The writer is an FT contributing editor and writes the Chartbook newsletter
本文作者是英国《金融时报》特约编辑，撰写Chartbook时事通讯
In a world of polycrisis, in which intersecting problems compound each other and there are few easy wins, it is all the more important to recognise those policy choices that are truly obvious. Vaccines are one such investment. Since the 1960s, global vaccination campaigns have eradicated smallpox, suppressed polio and contained measles. Modest expenditures on public health have saved tens of millions of lives, reduced morbidity and allowed children around the world to develop into adults capable of living healthy and productive lives.
在一个危机重重的世界里，问题相互交叉、加深彼此的复杂程度，而容易摘的果子没有多少，因此，认识到那些真正显而易见的政策选择就显得尤为重要。疫苗就是一项这样的投资。自20世纪60年代以来，全球疫苗接种运动已经根除了天花，基本消除了脊髓灰质炎并控制住了麻疹。不多的公共卫生支出挽救了无数人命，降低了发病率，并使世界各地的儿童得以成长为能够为社会做出贡献的健康的成年人。
After years of development, 2023 saw the approval of a second vaccine for malaria, a scourge which causes more than 600,000 deaths annually. A recent study on a vaccine for Strep A, a pathogen that causes 600,000 deaths and 600mn cases of pharyngitis annually, calculates that an investment of less than $60bn would deliver benefits in excess of $1.6tn.
经过多年的研发，第二种疟疾疫苗在2023年获得批准（疟疾每年造成60多万人死亡）。最近一项针对甲型链球菌疫苗的研究计算出，不到600亿美元的投资将带来超过1.6万亿美元的收益。甲型链球菌是一种每年导致60万人死亡和6亿例咽喉炎的病原体。
